Daniel Loeb Third Point
Daniel Loeb is the founder of Third Point, an event-driven and activist-oriented hedge fund. He is known for pointed letters to management teams, catalyst-driven investing, and a flexible mandate across equities and credit. Loeb’s campaigns and portfolio shifts regularly generate attention beyond specialist hedge fund circles.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$432M |
| 2 |
Charter Communications
CHTR
|
+$312M |
| 3 |
Sherwin-Williams
SHW
|
+$205M |
| 4 |
MON
Monsanto Co
MON
|
+$198M |
| 5 |
S&P Global
SPGI
|
+$172M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$450M |
| 2 |
DuPont de Nemours
DD
|
+$260M |
| 3 |
Roper Technologies
ROP
|
+$247M |
| 4 |
Yum! Brands
YUM
|
+$246M |
| 5 |
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
|
+$246M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.53% |
| 2 | Materials | 13.41% |
| 3 | Communication Services | 10.48% |
| 4 | Consumer Discretionary | 9.48% |
| 5 | Consumer Staples | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Baxter International
BAX
$13.6B
| $2.35B | 22.37% |
51,901,767
-1,948,233
| -4% | -$85.5M |
|
|
AGN
2
DELISTED
Allergan plc
AGN
| $1.13B | 10.79% |
4,900,000
-100,000
| -2% | -$23.1M |
|
|
3
DuPont de Nemours
DD
$18.7B
| $994M | 9.48% |
7,897,622
-1,974,406
| -20% | -$260M |
|
|
4
Meta Platforms (Facebook)
META
$1.4T
| $429M | 4.08% |
+3,750,000
| New | +$432M |
|
5
Danaher
DHR
$154B
| $389M | 3.71% |
5,728,153
+223,175
| +4% | +$14.6M |
|
|
6
Charter Communications
CHTR
$17.9B
| $332M | 3.16% |
+1,450,000
| New | +$312M |
|
7
Constellation Brands
STZ
$23.2B
| $331M | 3.15% |
2,000,000
+235,000
| +13% | +$36.8M |
|
8
Chubb
CB
$132B
| $307M | 2.93% |
2,350,000
-50,000
| -2% | -$6.16M |
|
9
TransDigm Group
TDG
$66.4B
| $298M | 2.84% |
1,131,000
+131,000
| +13% | +$32M |
|
10
Mohawk Industries
MHK
$9.23B
| $285M | 2.71% |
1,500,000
-500,000
| -25% | -$97.3M |
|
11
Alphabet (Google) Class A
GOOGL
$4.22T
| $281M | 2.68% |
8,000,000
-6,000,000
| -43% | -$220M |
|
12
AB InBev
BUD
$155B
| $250M | 2.38% |
1,900,000
+150,000
| +9% | +$18.9M |
|
13
Lowe's Companies
LOW
$121B
| $238M | 2.26% |
3,000,000
| – | – |
|
|
14
Yum! Brands
YUM
$41.8B
| $207M | 1.98% |
3,477,500
-4,173,000
| -55% | -$246M |
|
|
SEE
15
DELISTED
Sealed Air
SEE
| $207M | 1.97% |
4,500,000
-500,000
| -10% | -$23.9M |
|
|
MON
16
DELISTED
Monsanto Co
MON
| $207M | 1.97% |
+2,000,000
| New | +$198M |
|
|
17
Sherwin-Williams
SHW
$84.1B
| $206M | 1.96% |
+2,100,000
| New | +$205M |
|
|
BID
18
DELISTED
Sotheby's
BID
| $183M | 1.74% |
6,660,925
| – | – |
|
|
SHPG
19
DELISTED
Shire pic
SHPG
| $175M | 1.67% |
+950,000
| New | +$172M |
|
|
20
S&P Global
SPGI
$127B
| $172M | 1.64% |
+1,600,000
| New | +$172M |
|
|
EMC
21
DELISTED
EMC CORPORATION
EMC
| $163M | 1.55% |
6,000,000
-1,000,000
| -14% | -$27M |
|
22
Ametek
AME
$54.9B
| $125M | 1.19% |
+2,700,000
| New | +$130M |
|
|
ATVI
23
DELISTED
Activision Blizzard
ATVI
| $119M | 1.13% |
+3,000,000
| New | +$110M |
|
24
Union Pacific
UNP
$183B
| $118M | 1.12% |
+1,350,000
| New | +$114M |
|
|
AGN
25
CALL
DELISTED
Allergan plc
AGN
| $116M | 1.1% |
+500,000
| New | +$115M |
|
Similar funds
Daniel Loeb's Q2 2016 Portfolio in Review
As of Q2 2016, Daniel Loeb held 56 positions worth $10.5B, down 3.4% from $10.9B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Daniel Loeb withdrew a net $501M in Q2 2016, closing 16 positions and reducing 10 holdings. Its most notable exit was Amgen, an estimated $450M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Materials and Communication Services.
Against the trend, Daniel Loeb opened a new position in Meta Platforms (Facebook) worth $429M.
- Daniel Loeb's largest Q2 2016 buy was Meta Platforms (Facebook): 3,750,000 shares worth $429M.
- Daniel Loeb added most to Constellation Brands in Q2 2016, an estimated $36.8M increase.
- Daniel Loeb's biggest Q2 2016 reduction was DuPont de Nemours, cutting an estimated $260M.
- Daniel Loeb fully exited Amgen in Q2 2016, selling an estimated $450M.
- Daniel Loeb's ten largest holdings make up 65% of its $10.5B portfolio in Q2 2016.
- Daniel Loeb opened 19 new positions and closed 16 in Q2 2016.
- Daniel Loeb's portfolio value fell 3.4% quarter-over-quarter to $10.5B.
Based on Third Point's 13F filing for Q2 2016, filed 12 Aug 2016.